Genaphar SA
The score of Genaphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +2 % Total assets +27 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Genaphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 18,373 € | ||||
| Equity | 97,645 € | ||||
| Cash | 78,052 € | ||||
| EBITDA | 17,966 € | ||||
| Total assets | 147,330 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Sep 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Genaphar's financial analysis
- Solvency66.3%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Genaphar
Genaphar's publications in the Belgian Gazette
No Belgian Gazette publication known for this company.
Company number, VAT number and registered office
- Company number (CBE)
- 0416.169.095
- VAT number
- BE0416169095
- Peppol
- Registered · 0208:0416169095 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 04 Jun 1976
- Registered office
- 1000 Brussels
- Latest accounts
- 2025 · filed on 24 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Genaphar (SA) has been based in Brussels since 1976, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 18,373 € and equity of 97,645 €; its revenue is not published. Its solvency stands at 66.3%, above the median of its sector (37.8%).
Companies similar to Genaphar
Companies in the same business, of comparable size and area, outside its group.
- Louka Services Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 146,913 €
- Pharmacie DE Bousval Retail sale of pharmaceutical products Genappe · balance sheet 139,616 €
- Pharmattou Retail sale of pharmaceutical products Asse · balance sheet 146,566 €
- Jetpharma Retail sale of pharmaceutical products Jette · balance sheet 146,419 €
- Laura Cufaro Retail sale of pharmaceutical products Engis · balance sheet 145,385 €
- Apotheek Houben - Swinnen Retail sale of pharmaceutical products Genk · balance sheet 145,008 €
- X - Pharma Retail sale of pharmaceutical products Verviers · balance sheet 150,150 €
- Un Coquelicot Orange Retail sale of pharmaceutical products Courcelles · balance sheet 150,628 €
Frequently asked questions about Genaphar
What is the revenue of Genaphar?
Genaphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Genaphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0416169095 for Genaphar, if the company is VAT-registered. Its company number (CBE) is 0416.169.095.
Where is the registered office of Genaphar?
According to the CBE register, the registered office of Genaphar is in 1000 Brussels.
What is the equity of Genaphar?
At the close of the 2025 financial year, the equity of Genaphar amounts to 97,645 €, a solvency of 66.3% of total assets.
Who manages Genaphar?
The register lists 2 active mandates at Genaphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Genaphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →